阿德木单抗
| 单克隆抗体 | |
|---|---|
| 种类 | 完整抗体 |
| 目标 | EpCAM |
| 临床资料 | |
| ATC码 |
|
| 识别信息 | |
| CAS号 | 503605-66-1  |
| ChemSpider |
|
| UNII | |
| 化学信息 | |
| 化学式 | C6552H10080N1740O2052S46 |
| 摩尔质量 | 147,533.60 g·mol−1 |
阿德木单抗（INN：Adecatumumab；开发代号：MT201）是一种重组人IgG1单克隆抗体，用于靶向肿瘤细胞。它与上皮细胞黏附分子 (EpCAM - CD326) 结合，旨在触发抗体依赖性细胞毒性。它是由Micromet Inc开发的，该公司被安进收购。[1]
阿德木单抗已用于治疗结直肠癌、前列腺癌[2]和乳腺癌[3]的临床研究。II期研究结果于2010年发表。[4]
参考资料
- ^ Adecatumumab - Amgen/Merck Serono. Adis Insight. Springer Nature Switzerland AG. [2024-01-22]. （原始内容存档于2017-11-03）.
- ^ Oberneder R, Weckermann D, Ebner B, Quadt C, Kirchinger P, Raum T, et al. A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients. European Journal of Cancer. October 2006, 42 (15): 2530–8. PMID 16930989. doi:10.1016/j.ejca.2006.05.029.
- ^ Prang N, Preithner S, Brischwein K, Göster P, Wöppel A, Müller J, et al. Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines. British Journal of Cancer. January 2005, 92 (2): 342–9. PMC 2361858
. PMID 15655555. doi:10.1038/sj.bjc.6602310.
- ^ Schmidt M, Scheulen ME, Dittrich C, Obrist P, Marschner N, Dirix L, et al. An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer. Annals of Oncology. February 2010, 21 (2): 275–82. PMID 19633042. doi:10.1093/annonc/mdp314 .
